Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions.
The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022.
The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -0.25 Decreased by -96.54% | -0.22 Decreased by -13.64% |
| Aug 11, 25 | -0.34 Increased by +47.16% | -0.26 Decreased by -30.77% |
| May 12, 25 | -0.34 Decreased by -56.61% | -0.23 Decreased by -47.83% |
| Mar 31, 25 | -0.28 Decreased by -29.05% | -0.10 Decreased by -183.90% |
| Nov 12, 24 | -0.13 Increased by +14.23% | -0.10 Decreased by -27.20% |
| Aug 13, 24 | -0.64 Decreased by -373.09% | - |
| Apr 1, 24 | -0.22 Increased by +36.48% | - |
| Feb 14, 24 | -0.22 Decreased by -46.67% | -0.28 Increased by +21.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -13.44 M Decreased by -144.76% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -16.05 M Increased by +42.12% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -15.03 M Decreased by -34.81% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 168.00 K Increased by +N/A% | -12.46 M Decreased by -40.07% | Decreased by -7.42 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -5.49 M Decreased by -2.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -27.73 M Decreased by -467.52% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 36.00 K Increased by +N/A% | -11.15 M Increased by +9.02% | Decreased by -30.97 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -8.89 M Decreased by -60.72% | Decreased by N/A% Decreased by N/A% |